Home › Market › 2026-09-22

US Stock Analysis and Analyst Forecasts — September 22, 2026

Viking Therapeutics closed up 35.67% on VK2735 maintenance data and Micron rose 5.00% into its September 30 earnings, while Charles Schwab fell 6.10% and dragged financials lower on Vanguard's Altruist deal, and Apple ended just short of a $5 trillion market value.

None of the following is our own view on any stock — it is a same-day record of market action, analyst-firm calls and company news across the tracked universe on Tuesday, September 22, 2026.

U.S. stocks finished Tuesday split along sector lines. The S&P 500 ended essentially where it started, at 7,764.27, down less than 0.01%, while the Nasdaq 100 added 0.82% to 30,730.84 and the Dow Jones Industrial Average fell 0.36% to 51,863.69. Oil drove the morning and then reversed: Brent traded below $100 a barrel after Saudi Arabia said its East-West pipeline had resumed operations following the September 13 drone attack, then climbed back above that level once it emerged that the line could need several weeks to return to the four million barrels a day it carried before the strike. U.S. crude settled at $93.71, down 2.43%. Traffic through the Strait of Hormuz stayed severely constrained, with only two commodity vessels crossing on Monday against 10 the day before, according to cargo-tracking data. The United Nations General Assembly opened in New York, where President Trump said he would be willing to meet Iranian President Masoud Pezeshkian on the sidelines if conditions allowed, and separately said he expects the two countries to sign a deal after the November 3 midterm elections; Iran has not said whether it would attend such a meeting. Gold rose 0.42% to $4,361.70 and bitcoin slipped 0.44% to about $86,215.

Financials were the day's weak spot, and the driver was competitive rather than macro. Charles Schwab (SCHW) fell 6.10% to $100.36 after Vanguard agreed to acquire Altruist, a move read as an acceleration of Vanguard's plans to push artificial intelligence into advice and financial planning — a threat Schwab's own recently announced AI partnership was meant to answer. The selling spread across the sector: JPMorgan Chase (JPM) lost 3.40% to $340.07 and Morgan Stanley (MS) 2.84% to $200.26. JPMorgan supplied a second, separate headline of its own. Natasha Kaneva, the bank's head of global commodities strategy, told clients the firm no longer has a baseline crude forecast at all, writing that it does not know how to model the end of the Iran conflict now in its seventh month. The bank had assumed a set of economic red lines — crude above $100, retail gasoline near $5 a gallon, a 10-year Treasury yield above 5% — would force a deal to reopen the Strait of Hormuz. All three have since been crossed, diesel has passed $6 a gallon for the first time, and the exit is no clearer. JPMorgan puts fair value for Brent at roughly $90. Analysts hold a Moderate Buy consensus on JPMorgan itself, on 10 Buys and six Holds, with a $378.67 average target about 11% above Tuesday's close. Cisco (CSCO) fell 4.50% to $106.44 and Salesforce (CRM) 1.33% to $233.28.

Apple (AAPL) spent the afternoon on course for a milestone it did not quite reach. The stock was up 0.68% in late-afternoon trading, which would have carried its market value through $5 trillion for the first time, but it gave most of that back and closed at $339.75, up 0.23%, for a market capitalisation of about $4.96 trillion — short of the mark, though only just. Apple crossed $4 trillion less than a year ago, on October 28, 2025, and has gained roughly 10% in the past month. Part of the appeal, on the reading circulating among analysts, is what Apple is not doing: it is adding AI features to its devices without the heavy data-centre spending and borrowing that other large technology companies have taken on. The company also has a new chief executive, John Ternus, who succeeded Tim Cook on September 1, and it launched its first foldable iPhone, the Duo, together with an AI-equipped Siri earlier this month. The Street is split: a Moderate Buy consensus on 16 Buys, 12 Holds and four Sells, with a $334.51 average target that now sits about 1.5% below the closing price.

Nvidia (NVDA) rose 0.66% to $228.87, and the argument around it is increasingly about multiple rather than momentum. The stock changes hands at under 17 times expected earnings for the next 12 months, close to its cheapest in more than a decade, even as the Street models roughly 90% revenue growth and 99% net income growth in fiscal 2027. That is down from above 25 times forward earnings as recently as May. Chief executive Jensen Huang has called the company the first and only growth value stock and said it is badly misunderstood; a portfolio manager at TCW offered the other reading, that the valuation implies the market expects weaker results than analysts currently forecast. Two pressures sit behind the de-rating: gross margin, 75% in the second quarter, is expected to fall below 72% in the fourth before recovering, partly on higher memory costs, and several of Nvidia's largest customers are building their own accelerators. Nvidia is up about 22% in 2026, second among the megacap technology names behind Apple, while the semiconductor index has gained close to 76%. Analysts have a Strong Buy consensus on 31 Buys, with a $324.32 average target roughly 42% above the close.

The rest of the chip complex was firmer. Advanced Micro Devices (AMD) added 1.34% to $623.77, and its market value now stands at about $1.02 trillion — it recently became the fourth chipmaker to pass $1 trillion, after setting a record intraday high of $613.92. Intel (INTC) rose 1.71% to $123.86, and the comparison is awkward: Intel has rallied more than 300% over the past year and is still well short of that threshold, with AMD taking share in both data-centre CPUs and the GPU market Intel is largely absent from. The Street remains cautious on Intel, with a Hold consensus on seven Buys, 23 Holds and two Sells and a $117.56 average target about 5% below the close. Arm Holdings (ARM) gained 3.19% to $333.20, Qualcomm (QCOM) 2.08% to $198.27, TSMC (TSM) 1.52% to $451.89 and Broadcom (AVGO) 0.52% to $364.54. In deal news, Cognex — outside our coverage — agreed to buy RealSense, a former Intel spinoff, in a transaction valued at more than $600 million, including $500 million in cash and $56.5 million set aside to retain staff; Cognex shares fell 4.87%.

Memory was the strongest corner of the market. Micron (MU) closed up 5.00% at $1,096.16, extending a four-day run, and SanDisk — which is not in our tracked universe — rose 6.82% to $1,887.04. Micron reports fiscal fourth-quarter results on September 30, and expectations have climbed with the share price on AI-driven demand, tight supply and firmer pricing; investors will be watching high-bandwidth memory sales, DRAM pricing, gross margin, bit shipments and capacity plans. Stifel's Brian Chin reiterated a Buy rating and a $1,500 target, arguing that limited memory availability could keep favourable pricing in place longer than the market assumes. Coverage is close to unanimous: 29 of the 30 analysts following Micron rate it a Buy and one is neutral, producing a Strong Buy consensus and a $1,564.44 average target roughly 43% above Tuesday's close. SanDisk's move had a specific cause — Rosenblatt's Kevin Cassidy began coverage at Buy with a $2,400 target, on the argument that moving NAND storage physically closer to compute raises its value in AI systems.

Healthcare produced the day's largest single move. Viking Therapeutics (VKTX) closed up 35.67% at $40.85 after reporting positive top-line results from the maintenance study of VK2735, its dual GLP-1 and GIP receptor agonist. Patients who stepped down to injections every other week held on to as much as 97% of the weight they had already lost over a further 12 weeks, and those moved to monthly dosing kept as much as 90%, against 61% for patients switched to placebo. A separate exploratory group that stayed on a weekly 17.5-milligram dose reached 21.7% average weight loss from baseline after 33 weeks, compared with a 0.3% gain on placebo, with no sign of a plateau. Tolerability was the part analysts fastened on: gastrointestinal side effects during the maintenance window were not meaningfully different from placebo, with vomiting in single digits across both step-down regimens and no moderate or severe nausea reported. Truist's Gregory Renza said the data strengthens the case for the drug across both the initial weight-loss and maintenance phases, and Oppenheimer raised its target on the stock to $120. Volume ran above 15 million shares against a three-month daily average of roughly 1.84 million. Viking's two Phase 3 injectable trials have completed enrolment at about 4,500 and 1,000 participants, a Phase 3 programme for the oral version is expected to begin in the fourth quarter, and the company ended June with $502 million in cash and investments, which it expects to fund operations into 2028. All 14 covering analysts rate it a Buy, with a $90.08 average target more than double the close. Elsewhere in the sector, Amgen (AMGN) rose 4.34% to $410.24 after its Phase 3 OASIZ 301 trial of dazodalibep met its primary endpoint in adults with Sjögren's disease, though Citi noted that the drug's competitive profile remains an open question, and Moderna (MRNA) gained 5.56% to $182.56 on what options data suggested was bullish positioning rather than any company announcement we could verify.

Among the day's company news, Microsoft (MSFT) fell 0.72% to $498.00 after Xbox set out the next stage of its restructuring: Activision takes on more work across World's Edge and Rare and will build the next Halo through a dedicated team separate from Call of Duty, Bethesda absorbs Obsidian, King picks up Microsoft Casual Games, and Playground and Turn 10 merge around the Forza and Fable franchises. The changes come with 268 layoffs across Halo Studios, other first-party studios and central management. Microsoft carries a Strong Buy consensus on 33 Buys and two Holds with a $571.72 average target, about 15% above the close. Boeing (BA) fell 1.71% to $197.72 despite winning a Federal Aviation Administration exemption allowing it to build another 35 777 freighters; without it, production would have had to stop in 2028 under emissions rules, and the replacement aircraft has been delayed for years by certification. Tesla (TSLA) rose 0.96% to $378.90 after receiving its first credit rating from Fitch, an investment-grade BBB, which the agency tied to Tesla's position in battery electric vehicles and its shift toward physical AI while flagging the additional debt that shift is likely to require. Looking ahead inside the tracked universe, Costco (COST, up 0.10% to $899.41) reports fiscal fourth-quarter results after the close on Thursday, September 24, with the Street looking for revenue of $94.85 billion and adjusted earnings of $6.55 a share; Evercore ISI's Greg Melich reaffirmed a Buy rating and a $1,100 target and flagged a rising chance of a special dividend, though not at this week's print. As always: a price target is one firm's estimate rather than a forecast of what a stock will do, a one-day move on trial data or a competitor's acquisition can reverse just as quickly, and none of this is a recommendation to buy or sell anything.

Tickers in this brief

Published 2026-09-22. Market commentary, not investment advice. Prices are delayed end-of-day data.